Video

Dr. Haakensen on Exclusion Criteria of a Named Patient Use Program in NSCLC

Vilde D. Haakensen, MD, PhD, discusses exclusion criteria for the Oslo University Hospital Named Patient Use program for adjuvant durvalumab in non–small cell lung cancer.

Vilde D. Haakensen, MD, PhD, project group leader, researcher, Oslo University Hospital, discusses exclusion criteria for the Oslo University Hospital Named Patient Use program for adjuvant durvalumab (Imfinzi) in non–small cell lung cancer (NSCLC).

During the 2021 SOHO Annual Meeting, findings from a real-world experience study of adjuvant durvalumab in patients with locally advanced NSCLC were presented. Of the 41 patients included in the program, 35 patients started treatment with 1 year of durvalumab. The 6 patients excluded were so because of progression, wrong staging, pneumonitis, cardiac rheumatic disease, and osteomyelitis. An additional 8 patients stopped durvalumab because of adverse effects. 

It was important to examine why these patients could not start or complete durvalumab, which is associated with clinical benefit in this patient population, Haakensen concludes.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.